Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022
08:30pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first qu
Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028
10:50am, Tuesday, 19'th Apr 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with
OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
07:53pm, Monday, 11'th Apr 2022 Zacks Investment Research
Here is how Eagle Pharmaceuticals (EGRX) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
05:18pm, Monday, 11'th Apr 2022
Here is how Eagle Pharmaceuticals (EGRX) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Eagle Pharma Adds Hospital-Based Products With €95M Acacia Pharma Deal
11:50am, Monday, 28'th Mar 2022
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has agreed to acquire Acacia Pharma Group plc for approximately €94.7 million, equivalent to €0.90 per share. Each shareholder of Acacia Pharma would re
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
08:00am, Monday, 28'th Mar 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has reached agreement on the terms of a tran
Is Eagle Pharmaceuticals (EGRX) Stock Outpacing Its Medical Peers This Year?
11:18am, Tuesday, 15'th Mar 2022
Here is how Eagle Pharmaceuticals (EGRX) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call Transcript
07:02pm, Monday, 07'th Mar 2022 Seeking Alpha
Eagle Pharmaceuticals (EGRX) Q4 2021 Earnings Call Transcript
05:30pm, Monday, 07'th Mar 2022 The Motley Fool
EGRX earnings call for the period ending December 31, 2021.
Eagle Pharmaceuticals (EGRX) Q4 2021 Earnings Call Transcript
05:30pm, Monday, 07'th Mar 2022 The Motley Fool
EGRX earnings call for the period ending December 31, 2021.
Eagle Pharma''s Q4 Earnings Miss Street View On Lower Product Sales
05:05pm, Monday, 07'th Mar 2022 Benzinga
Eagle Pharmaceuticals Inc''s (NASDAQ: EGRX ) Q4 FY21 sales declined 15% Y/Y to $42.3 million , missing the consensus of $51.08 million. The sales declined primarily due to lower product sales of Belrapzo and Ryanodex and lower royalty revenue of Bendeka, partially offset by higher product … Full story available on Benzinga.com
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call Transcript
02:02pm, Monday, 07'th Mar 2022
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call Transcript
Eagle Pharmaceuticals Non-GAAP EPS of $0.85 misses by $0.09, revenue of $42.32M misses by $8.76M (NASDAQ:EGRX)
11:52am, Monday, 07'th Mar 2022 Seeking Alpha
Eagle Pharmaceuticals press release (EGRX): Q4 Non-GAAP EPS of $0.85 misses by $0.09.Revenue of $42.32M (-15.2% Y/Y) misses by $8.76M.“With two important launches in early 2022,…
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results
11:50am, Monday, 07'th Mar 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve mont
